Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 446 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: GLP 1 Clear all

Conditions: Obesity, Overweight, Weight Maintenance
Interventions: VRB-101, Placebo; Drug
Lead sponsor: Verdiva Bio Dev Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 20
States / cities: Cullman, Alabama • Phoenix, Arizona • Tempe, Arizona + 16 more

Conditions: Opiate Substitution Treatment, Opioid-Related Disorders
Interventions: Liraglutide Pen Injector, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Parkinson's Disease
Interventions: Exenatide; Drug
Lead sponsor: University of Florida; Other
Eligibility: 40 Years to 77 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Type 1 Diabetes, Obesity, Overweight
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 905 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 31
States / cities: Santa Barbara, California • Santa Clarita, California • Aurora, Colorado + 27 more

Conditions: Healthy
Interventions: Active Comparator: Sitagliptin, Placebo Comparator - No Sitagliptin; Drug
Lead sponsor: David D'Alessio, M.D.; Other
Eligibility: 35 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: Empagliflozin, DPP-4 inhibitor, GLP-1 receptor agonist; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 230,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes, Diabetes Mellitus, Type 2
Interventions: Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 32
States / cities: Tempe, Arizona • Corona, California • Gardena, California + 28 more

Conditions: Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity
Interventions: Semaglutide, Berobenatide, Tirzepatide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 24
States / cities: Birmingham, Alabama • Canoga Park, California • Los Angeles, California + 20 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, placebo, moxifloxacin, electrocardiogram (ECG); Drug · Procedure
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Colorectal Cancer Prevention, Colorectal Adenoma
Interventions: Tirzepatide; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bariatric Surgery
Interventions: GLP-1; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 1 Diabetes
Interventions: Closed loop with sensor and Insulin, Closed loop with sensor, Insulin and Liraglutide; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 40 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Type 2 Diabetes, Overweight, Obesity
Interventions: Liraglutide, Metformin; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: liraglutide, placebo, CMS Intensive Behavior Therapy; Drug · Behavioral
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 10
States / cities: Jacksonville, Florida • Plantation, Florida • Chicago, Illinois + 7 more

Conditions: Type 1 Diabetes
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Williamsville, New York

Conditions: Aging, LONGEVITY 1
Interventions: Zepbound; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 55 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Diabetes, Diabetes Mellitus Type 2
Interventions: Liraglutide, Metformin, Placebo, NNC0090-2746; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 20
States / cities: Chino, California • Hawaiian Gardens, California • Los Angeles, California + 17 more

Conditions: Psoriasis, Obesity
Interventions: Ixekizumab, Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 68
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 57 more

Conditions: Obesity
Interventions: HM11260C, Placebo; Biological
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 297 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Obesity
Interventions: Egg breakfast (EB), Weight Loss Counseling, Weight Loss Diet, Cereal Breakfast (CB); Behavioral
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions: Tirzepatide, Placebo; Drug · Other
Lead sponsor: T. John Winhusen, PhD; Other
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 6 more

Conditions: Type 2 Diabetes
Interventions: HM11260C, liraglutide, Placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: CA, California

Conditions: Normal Cellular Metabolism
Interventions: Somatostatin, Glucagon; Drug
Lead sponsor: K. Sreekumaran Nair; Other
Eligibility: 18 Years to 45 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Crohn Disease (CD)
Interventions: Tirzepatide, Standard of care treatment; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Beverly Hills, California • St Louis, Missouri • New York, New York

Search by objective public record fields.

A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

Effects of Exenatide on Motor Function and the Brain

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

DPP4 Inhibition & Beta Cell Function

Comparative Effectiveness of Empagliflozin in the US

A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors

The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition

Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting

Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes

Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting

Liraglutide in the Treatment of Type 1 Diabetes Mellitus

Tirzepatide to Slow Biological Aging

A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Effect of LAPS-Exendin on Body Weight in Obese Population

High Quality Protein for Assisting With Weight Loss

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

In Vivo Assessment of Cellular Metabolism in Humans

Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease